SmartInvest graduation capital will guide its portfolio companies from inception, through R&D, international market penetration, and fundraising SmartStart mentorship, advice and Venture Capital investment.
BioProtect Ltd., a platform technology company, provides innovative biodegradable “spacers” for use in radiation therapy treatment and general surgery. The major product, an absorbable balloon for prostate radiation treatment, has commercial clinical evidence to reduce highly undesirable and costly side effects, reduce treatment cost and improve patients’ quality of life. Following years of product development and clinical trials, the manufacturing capability and clinical protocols are well established and the Company seeks funding to support regulatory approval in the United States and associated commercial scale-up.
The BioProtect Prostate Balloon Implant is designed for prostate cancer patients undergoing external beam radiation therapy. The balloon is deployed in the prostate-rectal interspace and protects the rectum from harmful side effects of radiation therapy, such as rectal toxicity. The product was extensively tested in Europe, and is CE approved and commercially available. The product has been accepted with enthusiasm by opinion leaders in the United States and Europe
BioProtect core technology makes possible the design, development and manufacturing of implantable biodegradable balloon products in virtually any shape, form and space during the treatments of various conditions that require tissue and shape stability and protection.
The initial use of this technique is oncological and aimed to help patients undergoing radiation procedures for prostate cancer; The BioProtect balloon Implant dramatically reduces rectal toxicity in prostate cancer radiation therapy since this device allows for safe dose escalation and hypofractionation.
The biodegradable balloons degrade at a predetermined rate, depending on the type of application and radiation or surgical needs, and are ultimately completely absorbed in the patient’s body. The balloon is implanted through a proprietary, simple and quick insertion technique that supports a wide range of clinical applications in oncology and general surgery.
Recent sale of the product’s spin-off for orthopedic applications at a value of $34M.